<HTML><HEAD><META http-equiv="Content-type" content="text/html;charset=UTF-8"></HEAD><BODY><DIV><P><BR>               <BR>               <BR>               4 CONTRAINDICATIONS<BR>               <BR>                  Contraindications to peginterferon alfa and ribavirin also apply to VICTRELIS combination treatment.<BR>                  VICTRELIS in combination with peginterferon alfa and ribavirin is contraindicated in:<BR>                  <BR>                     Pregnant women and men whose female partners are pregnant because of the risks for birth defects and fetal death associated with ribavirin [see Warnings and Precautions (5.1) and Use in Specific Populations (8.1)].<BR>                     <BR>                        Patients with a history of a hypersensitivity reaction to boceprevir [see Warnings and Precautions (5.4)].<BR>                     <BR>                  <BR>                  Coadministration with drugs that are highly dependent on CYP3A4/5 for clearance, and for which elevated plasma concentrations are associated with serious and/or life-threatening events, including those in Table 2, is contraindicated [see also Drug Interactions (7)].<BR>                  <BR>                  Coadministration with potent CYP3A4/5 inducers, where significantly reduced boceprevir plasma concentrations may be associated with reduced efficacy, including those in Table 2, is contraindicated [see also Drug Interactions (7)].<BR>                  <BR><BR><table xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" width="100%" ID="t2"><BR>                     <caption>Table 2 Drugs that are contraindicated with VICTRELIS</caption><BR>                     <col width="33%" align="left" valign="top"/><BR>                     <col width="33%" align="left" valign="top"/><BR>                     <col width="34%" align="left" valign="top"/><BR>                     <thead><BR>                        <tr><BR>                           <th styleCode="Lrule Rrule" align="center" valign="middle">Drug Class</th><BR>                           <th styleCode="Rrule" align="center">Drugs Within Class that are Contraindicated With VICTRELIS</th><BR>                           <th styleCode="Rrule" align="center" valign="middle">Clinical Comments</th><BR>                        </tr><BR>                     </thead><BR>                     <tbody><BR>                        <tr styleCode="Botrule"><BR>                           <td styleCode="Lrule Rrule">Alpha 1-Adrenoreceptor antagonist</td><BR>                           <td styleCode="Rrule">Alfuzosin</td><BR>                           <td styleCode="Rrule">Increased alfuzosin concentrations can result in hypotension.</td><BR>                        </tr><BR>                        <tr styleCode="Botrule"><BR>                           <td styleCode="Lrule Rrule">Anticonvulsants</td><BR>                           <td styleCode="Rrule">Carbamazepine, phenobarbital, phenytoin</td><BR>                           <td styleCode="Rrule">May lead to loss of virologic response to VICTRELIS</td><BR>                        </tr><BR>                        <tr styleCode="Botrule"><BR>                           <td styleCode="Lrule Rrule">Antimycobacterial Agents</td><BR>                           <td styleCode="Rrule">Rifampin</td><BR>                           <td styleCode="Rrule">May lead to loss of virologic response to VICTRELIS.</td><BR>                        </tr><BR>                        <tr styleCode="Botrule"><BR>                           <td styleCode="Lrule Rrule">Ergot Derivatives </td><BR>                           <td styleCode="Rrule">Dihydroergotamine, ergonovine, ergotamine, methylergonovine</td><BR>                           <td styleCode="Rrule">Potential for acute ergot toxicity characterized by peripheral vasospasm and ischemia of the extremities and other tissues.</td><BR>                        </tr><BR>                        <tr styleCode="Botrule"><BR>                           <td styleCode="Lrule Rrule">GI Motility Agent</td><BR>                           <td styleCode="Rrule">Cisapride</td><BR>                           <td styleCode="Rrule">Potential for cardiac arrhythmias.</td><BR>                        </tr><BR>                        <tr styleCode="Botrule"><BR>                           <td styleCode="Lrule Rrule">Herbal Products</td><BR>                           <td styleCode="Rrule">St. John's Wort (hypericum perforatum)</td><BR>                           <td styleCode="Rrule">May lead to loss of virologic response to VICTRELIS.</td><BR>                        </tr><BR>                        <tr styleCode="Botrule"><BR>                           <td styleCode="Lrule Rrule">HMG-CoA Reductase Inhibitors</td><BR>                           <td styleCode="Rrule">Lovastatin, simvastatin</td><BR>                           <td styleCode="Rrule">Potential for myopathy, including rhabdomyolysis.</td><BR>                        </tr><BR>                        <tr styleCode="Botrule"><BR>                           <td styleCode="Lrule Rrule">Oral Contraceptives</td><BR>                           <td styleCode="Rrule">Drospirenone  </td><BR>                           <td styleCode="Rrule">Potential for hyperkalemia.</td><BR>                        </tr><BR>                        <tr styleCode="Botrule"><BR>                           <td styleCode="Lrule Rrule">PDE5 enzyme Inhibitor</td><BR>                           <td styleCode="Rrule">REVATIO<sup>&#174;</sup> (sildenafil) or ADCIRCA<sup>&#174;</sup> (tadalafil) when used for the treatment of pulmonary arterial hypertension<footnote>See <content styleCode="italics"><BR>                                    <linkHtml href="#t5">Drug Interactions, Table 5 </linkHtml><BR>                                 </content> for coadministration of sildenafil and tadalafil when dosed for erectile dysfunction.</footnote><BR>                           </td><BR>                           <td styleCode="Rrule">Potential for PDE5 inhibitor-associated adverse events, including visual abnormalities, hypotension, prolonged erection, and syncope.</td><BR>                        </tr><BR>                        <tr styleCode="Botrule"><BR>                           <td styleCode="Lrule Rrule">Neuroleptic</td><BR>                           <td styleCode="Rrule">Pimozide</td><BR>                           <td styleCode="Rrule">Potential for cardiac arrhythmias.</td><BR>                        </tr><BR>                        <tr><BR>                           <td styleCode="Lrule Rrule">Sedative/Hypnotics</td><BR>                           <td styleCode="Rrule">Triazolam; orally administered midazolam<footnote>See <content styleCode="italics"><BR>                                    <linkHtml href="#t5">Drug Interactions, Table 5 </linkHtml><BR>                                 </content>  for parenterally administered midazolam.</footnote><BR>                           </td><BR>                           <td styleCode="Rrule">Prolonged or increased sedation or respiratory depression.</td><BR>                        </tr><BR>                     </tbody><BR>                  </table><BR>               <BR><BR><BR><BR>               <BR>               <BR>                  <BR>                     <BR>                        <BR>                           <BR>                              All contraindications to peginterferon alfa and ribavirin also apply since VICTRELIS must be administered with peginterferon alfa and ribavirin. (4)<BR>                           <BR>                           Because ribavirin may cause birth defects and fetal death, boceprevir in combination with peginterferon alfa and ribavirin is contraindicated in pregnant women and in men whose female partners are pregnant. (4)<BR>                           Contraindicated in patients with a history of a hypersensitivity reaction to boceprevir. (4)<BR>                           Coadministration with drugs that are highly dependent on CYP3A4/5 for clearance, and for which elevated plasma concentrations are associated with serious and/or life-threatening events is contraindicated. (4)<BR>                           Coadministration with potent CYP3A4/5 inducers where significantly reduced boceprevir plasma concentrations may be associated with reduced efficacy is contraindicated. (4)<BR>                        <BR>                     <BR>                  <BR>               <BR>            <BR>         </P></DIV></HTML>